期刊文献+

以睾酮为探针的HPLC法测定CYP3A1酶活性的方法学研究 被引量:1

Methodology Research on Determination of CYP3A1 Activity by HPLC with Testosterone as Probe
原文传递
导出
摘要 目的:建立以睾酮为探针测定大鼠CYP3A1酶活性的方法。方法:采用高效液相色谱法,以咪达唑仑为内标,样品用乙酸乙酯萃取后重溶进样,进行睾酮特异代谢物6-β-羟基睾酮(6-β-OHT)浓度测定的方法学研究。色谱柱为HypersilBDSC18,流动相为甲醇-Na2HPO4水溶液(pH8.25)(60:40),流速为1mL.min-1,检测波长为254nm。结果:6-β-OHT检测浓度线性范围为1.25~100μg.mL-1(r=0.9998),最低定量限为1.25μg.mL-1;萃取回收率为83.9%~87.4%(RSD≤8.82%),相对回收率为100.4%~103.4%(RSD≤7.05%);平均日内、日间RSD均<10%;样本室温放置4h稳定性良好。结论:所建立的方法快速、简便、重复性好,适用于体外定量测定睾酮及其代谢物6-β-OHT,也可用于体外评估CYP3A1酶的活性。 OBJECTIVE: To develop a method for the determination of CYP3A1 activities in rats with testosterone as probe. METHODS: HPLC method was adopted using midazolam as internal standard, and samples were extracted by ethyl-acetate, evapo- rated and re-dissolved. The method validation of the determination of 6-fl-hydroxytestosterone (6-β-OHT) concentration had been ex- amined. The determination was performed on Hypersil BDS C18 column with mobile phase consisted of methanol-Na2HPO4 (pH= 8.25) (60:40) at the flow rate of 1 mL.min-1. Detection wavelength was set at 254 nm. RESULTS: The linear range of 6-fl-OHT was 1.25-100tg.mL-1 (r=0.999 8). Limit of quantitation was 1.25 ~tg.mL-t. Extraction recoveries were 83.9%-87.4% (RSD≤8.82% ). Relative recoveries were 100.4%-103.4% (RSD≤7.05%). The RSD of intra-day and inter-day were less than 10%. Sample were stable at room temperature for 4 hours. CONCLUSION: The method is rapid, simple and repeatable. It's applicable to determination of testosterone and 6-fl-OHT in vitro. Also it's applicable for the evaluation of CYP3A1 activities in vitro.
出处 《中国药房》 CAS CSCD 2012年第25期2318-2320,共3页 China Pharmacy
基金 2009年广东省医学科研基金项目(B2009090)
关键词 高效液相色谱法 睾酮 6-β-羟基睾酮 咪达唑仑 肝微粒体 方法学 HPLC Testosterone 6-β--hydroxytestosterone Midazolam Liver microsomes Methodology
  • 相关文献

参考文献7

  • 1Venkatakrishnan K , Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models [J]. J Clin Pharma, 2001, 41(11):1 149.
  • 2Friedrich G, Rose T, Rissler K. Determination of testosterone metabolites in human hepatocytes I. Development of an on-line sample preparation liquid chromatography technique and mass spectroscopic detection of 6-β-hydroxytestosterone[J]. J Chromatog B, 2003,784( 1 ) :49.
  • 3Whalley PM, Bakes D, Grime K, et al. Rapid high-performance liquid chromategraphic method for the separation of hydroxylated testosterone metabolites[J]. J Chromatog B, 2001,760 (2) : 281.
  • 4Canistro D, Bonamassa B, Pozzetti L, et al. Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice[J]. Food and Chemical Toxicology, 2009,47(2) :454.
  • 5张荣,刘昌辉,王宁生,宓穗卿.以睾酮为探针采用高效液相色谱法测定细胞色素CYP450 3A4的酶活性[J].色谱,2008,26(1):80-83. 被引量:19
  • 6Batles MRH, Dubois JG, Hanoqu M. Ethylacetate extraction procedure and isocratic high-performance liquid chromatographic assay for testosterone metabolites in cell microsomes[J].J Chromatog B, 1998,706 ( 2 ) : 201.
  • 7刘彦卿,洪燕君,曾苏.代谢性药物-药物相互作用的研究进展[J].浙江大学学报(医学版),2009,38(2):215-224. 被引量:45

二级参考文献27

  • 1SCHROEDER W ,Ghobrial L ,Gandhi P. Possible mechanisms of drug-induced aspirin and clopidogrel resistance [J].Journal of Thrombosis and Thrombolysis, 2006,22 ( 2 ) : 139- 150.
  • 2COZZA K L, ARMSTRONG S C, OESTER HELD J R. Drug interactions by medical specialty. In:Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins [M]. 2nd ed. Washington D C: American Psychiatric Pub, 2003,167-396.
  • 3ZEVIN S, BENOWITZ N L. Drug Interactions with Tobacco Smoking : An Update[J]. Clinical Pharmacokinetics, 1999,36 : 425-438.
  • 4DE LEON J, DIAZ F J, ROGERS T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers [J]. Prog Neuropsychopharmaeol Biol Psychiatry, 2003,27 (1) : 165-171.
  • 5NGUYEN M ,CHUNG E P. Telithromycin :The first ketolide antimicrobial [J]. Clinical Therapeutics, 2005,27 (8) : 1144-1163.
  • 6SLAUGHTER R L, EDWARDS D J. Recent advances: the cytochrome P450 enzymes [J].Ann Pharmacother, 1995,29 : 619-624.
  • 7WEINSHILBOUM R. Inheritance and Drug Response [J]. N Engl J Med,2003,348(6): 529-537.
  • 8[Anonymous] Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status[J]. Technol Eval Cent Asses Program Exec Summ, 2004,19 : 1-2.
  • 9MICHALETS E L. Update :clinically significant cytochrome P-450 drug interactions [J]. Pharmacotherapy, 1998,18 : 84-112.
  • 10HUANG S M, TEMPLE R, THROCKMORTON D C, et al. Draft Guidance for Industry : Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labling [J]. Clin Pharmacol Ther, 2007,81 (2) : 298-304.

共引文献60

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部